Abstract:Background/Aim. The fact that lung carcinomas, like other solid tumours, can be immunogenic, may have a substantial prognostic value in non-small cell lung cancer. Specific cytotoxic T-lymphocytes can be demonstrated in most patients with primary tumours of different histological types. Two main groups of T-lymphocytes participate in the coupled recognition of tumour-specific antigens - cytotoxic T-lymphocytes (CD8+, cluster of differentiation 8) and helper T-lymphocytes (CD4+, cluster of differentiation 4). The main goal of this research was to assess the relationship between the tumour infiltration of T-lymphocytes and the therapeutic response to initial chemotherapy. Methods. Data were obtained from patients with non-small cell lung cancer whose therapeutic response after four cycles of initial platinum chemotherapy was observed in relation to the density of tumour-infiltrating T-lymphocytes (CD4+ and CD8+) in small tumour biopsy samples. The therapeutic response was assessed in line with RECIST 1.1. therapeutic response evaluation system. Based on the expected therapeutic response, the patients were divided into three following groups: favourable therapeutic response patients (complete and partial regression), stable disease patients and disease progression patients. To assess the density of CD4+ and CD8+ T-lymphocytes, the number of lymphocytes was determined at x200 (1.1mm2) magnification. Three visual fields with the most dense lymphocyte infiltrate were selected for counting, and the values of all individual fields were added up. Based on the mean value, the samples were classified into the following groups: score 0, 1, 2 and 3. During statistical processing of the data, low infiltration density combined score 0 and score 1 group, and high infiltration density combined score 2 and score 3 group. Based on the collected data, a database was created in SPSS 22.0 software and used for further statistical analysis. The statistical analysis of the data included the method of descriptive and analytical statistics. Results. The results did not show any difference in distribution of CD4+ T-lymphocytes in epithelial components between patients with a different therapeutical response (?2=2,977; p= 0.226). Also, there was not any significant difference in the distribution of CD8+ T-lymphocytes in epithelial component between patients with a different therapeutical response (?2=1,329; p=0.515). There was no significant influence of the infiltration density of CD4+ T-lymphocytes in the stromal component on the therapeutic response (?2=0,606; p=0.739) and also, there was no significant influence of the infiltration density of CD8+ T-lymphocytes in stromal component on the therapeutic response (?2=5,167; p=0.076). Conclusion. The research did not prove that patients with a high level of tumour-infiltrating CD4+ and CD8+ T-lymphocytes in the epithelial and stromal component of the tumour (non-small cell lung cancer) had a better therapeutic response to standard initial chemotherapy.

Prognostic significance of T lymphocyte subgroups (CD4 and CD8) in lung cancer patients after neoadjuvant chemotherapy

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer

The impact of the tumor immune microenvironment and tumor-infiltrating lymphocyte subgroups on laryngeal cancer prognosis

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures

Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients

The Relationship Between Lymphocyte Subsets and the Prognosis and Genomic Features of Lung Cancer: A Retrospective Study

The Clinical Values of Circulating Tumor Cells and T Lymphocyte Subsets in Predicting a Prognosis of Lung Cancer

Comprehensive Analysis of T-cell Receptor Sequencing in Resectable Squamous Cell Lung Cancer Patients with Neoadjuvant Therapy of PD-1 Inhibitor and Chemotherapy.

Integrative analysis of single-cell and bulk RNA-sequencing data revealed T cell marker genes based molecular sub-types and a prognostic signature in lung adenocarcinoma

The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.

Prognostic value of tumor-infiltrating T-lymphocytes density in the therapeutic response to initial platinum-based chemotherapy in patients with non-small cell lung cancer

Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinoma

Integration of Bioinformatics and Machine Learning to Identify CD8+ T Cell-Related Prognostic Signature to Predict Clinical Outcomes and Treatment Response in Breast Cancer Patients

Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients

Immunomodulatory Effects of Chemotherapy on Blood Lymphocytes and Survival of Patients with Advanced Non-Small Cell Lung Cancer

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions

CD8<SUP>+</SUP> T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma

P1-01-13: Prognostic Impact of CD8 in Node-Negative Breast Cancer.

TIGIT/CD47 Dual High Expression Predicts Prognosis and is Associated with Immunotherapy Response in Lung Squamous Cell Carcinoma.

B cell-dependent subtypes and treatment-based immune correlates to survival in stage 3 and 4 lung adenocarcinomas